According to ProQR's latest financial reports the company has $0.13 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.13 B | 29.54% |
2022-12-31 | $0.10 B | -52.21% |
2021-12-31 | $0.21 B | 127.67% |
2020-12-31 | $93.27 M | -25.62% |
2019-12-31 | $0.12 B | 3.83% |
2018-12-31 | $0.12 B | 109.17% |
2017-12-31 | $57.74 M | -7.34% |
2016-12-31 | $62.31 M | -39.92% |
2015-12-31 | $0.10 B | -24.35% |
2014-12-31 | $0.13 B | 2304.52% |
2013-12-31 | $5.7 M | 1631.24% |
2012-12-31 | $0.32 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Atara Biotherapeutics ATRA | $51.72 M | -60.66% | ๐บ๐ธ USA |
Agenus
AGEN | $76.11 M | -42.11% | ๐บ๐ธ USA |
Actinium Pharmaceuticals ATNM | $76.67 M | -41.68% | ๐บ๐ธ USA |